CBmed projects aim to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, therapy monitoring and a more personalized treatment of patients.

AREA 1: DATA & TECHNOLOGIES

As of 2019

  • Digital biomarkers for precision medicine (DBM4PM)
  • Multi-parameter core technologies: Immunology, Digital Pathology and Metabolomics
  • FUSION Technology

2015 – 2018

  • Clinical data management for biomarker research
  • Innovative use of information for clinical care and biomarker research
  • Knowledge discovery and advanced interactive data mining
  • Next generation sequencing-based biomarkers in molecular pathology
  • Metabolomics Platform for biomarker research
  • Immunology Platform for biomarker research
  • Health technology assessment
  • Digital Pathology
  • Clinical MALDI application

AREA 2: CANCER

As of 2019

  • Liquid biopsy in cancer
  • Translational molecular imaging agents for in-vitro and in-vivo application
  • Next-generation drug-screening platform for precision oncology services
  • Near-infrared light exposure in cancer

2015 – 2018

  • Circulating tumour cells and cell-free nucleic acids as biomarkers for disease monitoring
  • Tracking the trace: Detection, selection and target evaluation of cellular and cell-free cancer biomarkers
  • Blood based, broad-spectrum biomarker panels for cancer diagnostics
  • Minimal residual disease detection as a prognostic biomarker and therapeutic target in hematologic malignancies using monoclonal antibodies and development of therapeutic chimeric antibody receptor (CAR) T cells
  • Genomic, transcriptomic and proteomic evaluation of eukaryotic initiation factors (eIFs) in various tumour entities
  • Galpha12 and Galpha13 as prognostic biomarkers and inducers of apoptosis in solid cancers
  • MR-PDX-models for the evaluation of cancer treatments
  • Core Lab for target identification and in-vivo probe development
  • Fusion Technology: Colon Cancer Stage 2

AREA 3: CARDIO-METABOLIC HEALTH

As of 2019

  • Biomarkers for cardiometabolic health and disease
  • Biomarkers in acute cardio-reno-metabolic disease states
  • Diagnostic and predictive biomarkers in disorders of fertility and metabolism
  • Microbiome-based biomarkers

2015 – 2018

  • Biomarkers to address diabesity
  • Biomarkers in early detection and risk assessment of cardiovascular disease
  • Biosensors for short-lived biomarkers
  • Biomarkers of bone metabolism and related organ systems
  • Biomarkers in the regulation of fertility
  • Minimally-invasive biomarkers for liver function
  • In-vivo biomarkers for inflammation and fibrosis diagnosis and therapy monitoring
  • Minimally-invasive broad spectrum biomarkers for NAFLD diagnosis and monitoring
  • Biomarkers for probiotic effects on microbiome-gut-brain axis
  • Biomarkers for early sepsis detection
  • Molecular signatures as biomarkers of invasive fungal infections
  • Electrochemical biomarkers‚ detection in common metabolic disorders

> 50 INTERNATIONAL PARTNERS ON 4 CONTINENTS

The COMET Center CBmed is funded within COMET – Competence Centers for Excellent Technologies by the Federal Ministry of Transport, Innovation and Technology (BMVIT), the Federal Ministry for Digital and Economic Affairs (BMDW), Land Steiermark (Styrian Business Promotion Agency – SFG) and Land Wien (Vienna Business Agency – WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG).

CBmed GmbH Center for Biomarker Research in Medicine
Stiftingtalstrasse 5   8010 Graz   Austria   office@cbmed.at   +43 316 385 28801

PRESS CORNER     CONTACT     IMPRINT     PRIVACY

Font Resize
Contrast